Symbols

TSBX(Delisted)

Turnstone Biologics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TSBX

Turnstone Biologics Corp.

A clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors

Industry

Established Date

12/13/2018

Listing Date

07/21/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.turnstonebio.com

Security Type

Common stock

Office address

1110 North Virgil Avenue PMB 94659 , Los Angeles, California 90029

Business

Introduction

Turnstone Biologics Corp. was incorporated on December 13, 2018 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on developing new drugs to treat and cure patients with solid tumors. The approved immunotherapy represents a significant advance in the treatment of solid tumors, but many patients either do not respond or experience disease recurrence after an initial response. The company believes that the most significant challenge in creating therapeutic immunotherapies in these patients is the low number of T cells that can recognize and attack tumors, which the company calls tumor-reactive T cells. To solve this problem, the company is pioneering a differentiated approach for tumor-infiltrating lymphocytes (TILs).

Company Financials

EPS

TSBX has released its 2025 Q1 earnings. EPS was reported at -0.51, versus the expected -0.68, beating expectations. The chart below visualizes how TSBX has performed over recent quarters, highlighting trends in earnings surprises.